Dart Neuroscience, LLC

Vidya Therapeutics, Inc.

Dange Vijay Kumar

Brian Dyck

Brett C Bookser

Aaron Craig Burns

Nicholas Brian Raffaele

Joe Anh Tran

Michael I Weinhouse

Iriny Botrous

DeMichael Chung

Margaret McCarrick

Andrew Kleinke

Daniel J Buzard

Nidhi Arora

Craig Alan Coburn

Demichael Chung

Joe Tran

Michael Weinhouse

Margaret Mccarrick

Disclosed herein are 1H-indole-7-carboxamide derivatives as protein kinase inhibitors, in particular Bruton's tyrosine kinase (BTK) inhibitors, pharmaceutical compositions comprising them, processes for preparing them and uses of such protein kinase inhibitors to treat or prevent diseases, disorders and conditions associated with kinase function. In particular, the present invention relates to selective BTK inhibitors.

Kinase inhibitors

Substituted furanopyrimidine chemical entities of Formula (I): wherein Rhas any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.

Substituted furanopyrimidine compounds as PDE1 inhibitors

Substituted furanopyrimidine chemical entities of Formula (I): wherein Rhas any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders. 

Growing community of inventors

San Diego, CA, United States of America

Dange Vijay Kumar